Our Focus
The Colorado Chapter of the National Hemophilia Foundation (NHF Colorado) is responsible for addressing the challenges bleeding disorder patients and their families face through education, advocacy, and empowerment.
El Capítulo de Colorado de la Fundación Nacional de Hemofilia (NHF Colorado) es responsable de abordar los desafíos que enfrentan los pacientes con trastornos hemorrágicos y sus familias a través de la educación, la defensa y el empoderamiento. Visite nuestra página en español aquí.
Have you or a loved one been personally impacted by current legislation surrounding medical policies? We'd love to connect with you! Please click on the button below to get involved with the Chapter's advocacy efforts.
Our Mission ... In Action
-
We connect people in the bleeding disorder community to available, applicable resources and to one another. Through connection we don't have to go through this alone.
-
We fight to protect access to quality healthcare and treatments we need to live healthy lives, but we can't do it without your voice. Discover how you and your family can make a big difference by joining our advocacy efforts.
-
We are committed to trailblazing the way for those affected by bleeding disorders. We encourage our community members to step out into nature, to forage ahead on their own path of independence.
-
We are committed to educating people inside and outside the bleeding disorder community. Education is empowerment and we strive to encourage independence through learning.
News Articles
On November 22, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus (AAV) vector-based gene therapy. It is approved for the treatment of adults with hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
Historically, many residential substance use disorder (SUD) facilities have denied admittance to individuals with bleeding disorders – the basis of these denials are most often the use of self-administered, intravenous medications such a as factor replacement therapies. The lack of access to residential addiction treatment facilities, can have very serious, even fatal outcomes for bleeding disorder (BD) patients in acute need of help with their addiction.
OUR ADVERTISERS
